US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
EP1462450B1
(en)
*
|
1993-12-29 |
2007-06-13 |
MERCK SHARP & DOHME LTD. |
Substituted morpholine derivatives and their use as therapeutic agents
|
TW385308B
(en)
*
|
1994-03-04 |
2000-03-21 |
Merck & Co Inc |
Prodrugs of morpholine tachykinin receptor antagonists
|
AU690682B2
(en)
*
|
1994-05-05 |
1998-04-30 |
Merck Sharp & Dohme Limited |
Morpholine derivatives and their use as antagonists of tachikinins
|
GB9505491D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9523244D0
(en)
*
|
1995-11-14 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6117855A
(en)
*
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
US5750549A
(en)
*
|
1996-10-15 |
1998-05-12 |
Merck & Co., Inc. |
Cycloalkyl tachykinin receptor antagonists
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
ES2231902T3
(es)
*
|
1996-12-02 |
2005-05-16 |
MERCK SHARP & DOHME LTD. |
Uso de antagonistas del receptor de nk-1 para el tratamiento de transtornos del movimiento.
|
CA2273853A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating cognitive disorders
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
CA2273351A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating sexual dysfunction
|
CA2273856A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating bipolar disorders
|
US6613765B1
(en)
*
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
AU744261B2
(en)
*
|
1997-04-24 |
2002-02-21 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating eating disorders
|
AU737019B2
(en)
*
|
1997-08-04 |
2001-08-09 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating aggressive behaviour disorders
|
AU738047B2
(en)
*
|
1997-08-04 |
2001-09-06 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating mania
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
GB9813025D0
(en)
|
1998-06-16 |
1998-08-12 |
Merck Sharp & Dohme |
Chemical synthesis
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
WO2000050398A2
(en)
|
1999-02-24 |
2000-08-31 |
F. Hoffmann-La Roche Ag |
Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
|
AU772446B2
(en)
|
1999-02-24 |
2004-04-29 |
F. Hoffmann-La Roche Ag |
3-phenylpyridine derivatives and their use as NK-1 receptor antagonists
|
EP1035115B1
(en)
|
1999-02-24 |
2004-09-29 |
F. Hoffmann-La Roche Ag |
4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
|
US6291465B1
(en)
|
1999-03-09 |
2001-09-18 |
Hoffmann-La Roche Inc. |
Biphenyl derivatives
|
FR2792835B3
(fr)
*
|
1999-04-27 |
2001-05-25 |
Sanofi Sa |
Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
|
USRE39921E1
(en)
|
1999-10-07 |
2007-11-13 |
Smithkline Beecham Corporation |
Chemical compounds
|
GB9923748D0
(en)
*
|
1999-10-07 |
1999-12-08 |
Glaxo Group Ltd |
Chemical compounds
|
US6552025B1
(en)
*
|
1999-11-24 |
2003-04-22 |
Emory University |
Diimino-piperazine derivatives for use as modulators of cell regulation
|
DE60006340T2
(de)
*
|
1999-11-29 |
2004-09-09 |
F. Hoffmann-La Roche Ag |
2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
|
US6452001B2
(en)
|
2000-05-25 |
2002-09-17 |
Hoffmann-La Roche Inc. |
Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
|
US6482829B2
(en)
|
2000-06-08 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
|
WO2002006236A1
(en)
|
2000-07-14 |
2002-01-24 |
F. Hoffmann-La Roche Ag |
N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
|
TWI287003B
(en)
|
2000-07-24 |
2007-09-21 |
Hoffmann La Roche |
4-phenyl-pyridine derivatives
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
GB0025354D0
(en)
*
|
2000-10-17 |
2000-11-29 |
Glaxo Group Ltd |
Chemical compounds
|
YU39503A
(sh)
|
2000-11-22 |
2006-05-25 |
F. Hoffmann-La Roche Ag. |
Derivati pirimidina
|
US6642226B2
(en)
|
2001-02-06 |
2003-11-04 |
Hoffman-La Roche Inc. |
Substituted phenyl-piperidine methanone compounds
|
GB0108594D0
(en)
*
|
2001-04-05 |
2001-05-23 |
Glaxo Group Ltd |
Chemical compounds
|
US20030055026A1
(en)
*
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
US6849624B2
(en)
|
2001-07-31 |
2005-02-01 |
Hoffmann-La Roche Inc. |
Aromatic and heteroaromatic substituted amides
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
MY130373A
(en)
*
|
2001-10-29 |
2007-06-29 |
Malesci Sas |
Linear basic compounds having nk-2 antagonist activity and formulations thereof
|
US6903129B2
(en)
*
|
2001-12-14 |
2005-06-07 |
Hoffman-La Roche Inc. |
D-proline prodrugs
|
GB0203020D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Glaxo Group Ltd |
Chemical compounds
|
WO2003066589A1
(en)
*
|
2002-02-08 |
2003-08-14 |
Glaxo Group Limited |
Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
|
GB0203022D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Glaxo Group Ltd |
Chemical compounds
|
AR039625A1
(es)
*
|
2002-04-18 |
2005-03-02 |
Merck & Co Inc |
Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
|
US20060205724A1
(en)
*
|
2002-05-29 |
2006-09-14 |
The Regents Of The University Of California |
Antagonizing nk-1 receptors inhibits consumption of substances of abuse
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
NZ541243A
(en)
|
2003-01-31 |
2008-04-30 |
Hoffmann La Roche |
New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
|
JP4490421B2
(ja)
|
2003-07-03 |
2010-06-23 |
エフ.ホフマン−ラ ロシュ アーゲー |
統合失調症を処置するデュアルnk1/nk3アンタゴニスト
|
TWI359675B
(en)
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
TWI280239B
(en)
|
2003-07-15 |
2007-05-01 |
Hoffmann La Roche |
Process for preparation of pyridine derivatives
|
JP4795022B2
(ja)
*
|
2003-09-30 |
2011-10-19 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ヘテロ環化合物を含有する新規な抗真菌剤
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
KR20070007075A
(ko)
|
2003-12-31 |
2007-01-12 |
사이덱스 인크 |
술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
|
US20070020298A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
ES2246687B2
(es)
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
|
EP1730751B1
(en)
*
|
2004-03-12 |
2009-10-21 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
A magnetoresistive medium
|
WO2005104712A2
(en)
|
2004-04-23 |
2005-11-10 |
Cydex, Inc. |
Dpi formulation containing sulfoalkyl ether cyclodextrin
|
US7541357B2
(en)
|
2004-07-15 |
2009-06-02 |
Amr Technology, Inc. |
Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
US20090227799A1
(en)
*
|
2004-08-09 |
2009-09-10 |
Kazutaka Nakamoto |
Novel Antimalarial Agent Containing Heterocyclic Compound
|
US8088918B2
(en)
*
|
2004-08-11 |
2012-01-03 |
Williamsburg Holdings Llc |
Noncardiotoxic pharmaceutical compounds
|
US7223737B1
(en)
|
2004-08-13 |
2007-05-29 |
Alcon, Inc. |
Method of treating dry eye disorders using glycosides
|
AR051475A1
(es)
*
|
2004-11-05 |
2007-01-17 |
Merck & Co Inc |
Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
|
JP4767973B2
(ja)
|
2005-02-22 |
2011-09-07 |
エフ.ホフマン−ラ ロシュ アーゲー |
Nk1アンタゴニスト
|
RU2404969C2
(ru)
|
2005-03-23 |
2010-11-27 |
Ф. Хоффманн-Ля Рош Аг |
Метаболиты антагонистов nk-1 против рвоты
|
JP4874958B2
(ja)
*
|
2005-03-30 |
2012-02-15 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ピリジン誘導体を含有する抗真菌剤
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
GEP20125566B
(en)
|
2005-07-15 |
2012-07-10 |
Amr Technology Inc |
Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
|
CN101267808A
(zh)
|
2005-09-23 |
2008-09-17 |
弗·哈夫曼-拉罗切有限公司 |
新型制剂
|
AU2006297443B2
(en)
|
2005-09-29 |
2010-08-12 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
WO2007039883A2
(en)
*
|
2005-10-05 |
2007-04-12 |
Ranbaxy Laboratories Limited |
Process for preparation of aprepitant
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
TWI385169B
(zh)
*
|
2005-10-31 |
2013-02-11 |
Eisai R&D Man Co Ltd |
經雜環取代之吡啶衍生物及含有彼之抗真菌劑
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
EP1984359A1
(en)
*
|
2006-02-03 |
2008-10-29 |
Glenmark Pharmaceuticals Limited |
Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
|
JP2009526860A
(ja)
*
|
2006-02-15 |
2009-07-23 |
ティカ レーケメデル アーベー |
安定したコルチコステロイド混合物
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8183264B2
(en)
*
|
2006-09-21 |
2012-05-22 |
Eisai R&D Managment Co., Ltd. |
Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
JP4611444B2
(ja)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
|
WO2008090114A1
(en)
|
2007-01-24 |
2008-07-31 |
Glaxo Group Limited |
Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
|
CA2682727C
(en)
|
2007-04-02 |
2016-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Indoledione derivative
|
JP5203449B2
(ja)
|
2007-04-20 |
2013-06-05 |
エフ.ホフマン−ラ ロシュ アーゲー |
二重nk1/nk3受容体アンタゴニストとしてのピロリジン誘導体
|
CN102702185A
(zh)
*
|
2007-04-27 |
2012-10-03 |
卫材R&D管理有限公司 |
杂环取代吡啶衍生物的盐的结晶
|
TW200841879A
(en)
*
|
2007-04-27 |
2008-11-01 |
Eisai R&D Man Co Ltd |
Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
|
EP1994930A1
(en)
*
|
2007-05-22 |
2008-11-26 |
Novartis AG |
Triazol compounds for treating biofilm formation
|
EP3103791B1
(en)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
RU2010106974A
(ru)
|
2007-08-07 |
2011-09-20 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Ариловые эфиры пирролидина в качестве антагонистов рецепторов nk3
|
US20090076008A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched fosaprepitant
|
US20090076007A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched aprepitant
|
US8513287B2
(en)
|
2007-12-27 |
2013-08-20 |
Eisai R&D Management Co., Ltd. |
Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
|
CA2716080C
(en)
|
2008-02-20 |
2016-12-13 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
US8598184B2
(en)
|
2008-03-03 |
2013-12-03 |
Tiger Pharmatech |
Protein kinase inhibitors
|
US20100048912A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
CA2730681C
(en)
*
|
2008-07-17 |
2017-03-07 |
Glenmark Generics Limited |
Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations
|
US8188119B2
(en)
*
|
2008-10-24 |
2012-05-29 |
Eisai R&D Management Co., Ltd |
Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
|
EP2393827B1
(en)
|
2009-02-05 |
2015-10-07 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
WO2010106988A1
(ja)
|
2009-03-17 |
2010-09-23 |
第一三共株式会社 |
アミド誘導体
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
WO2010132487A1
(en)
|
2009-05-12 |
2010-11-18 |
Bristol-Myers Squibb Company |
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
|
PE20120373A1
(es)
|
2009-05-12 |
2012-05-17 |
Albany Molecular Res Inc |
7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
|
CN102458123A
(zh)
|
2009-05-12 |
2012-05-16 |
阿尔巴尼分子研究公司 |
芳基、杂芳基和杂环取代的四氢异喹啉及其用途
|
UY32799A
(es)
*
|
2009-07-24 |
2011-02-28 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
|
US8188079B2
(en)
*
|
2009-08-19 |
2012-05-29 |
Hoffman-La Roche Inc. |
3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
|
JP5099731B1
(ja)
|
2009-10-14 |
2012-12-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
p53活性を増大する置換ピペリジン及びその使用
|
WO2011045817A2
(en)
*
|
2009-10-15 |
2011-04-21 |
Sandoz Private Limited |
Process for the preparation of fosaprepitant, intermediate and pharmaceutical acceptable salt thereof
|
WO2011120044A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Duke University |
Conjugated neuroactive steroid compositions and methods of use
|
US8487102B2
(en)
|
2010-04-20 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
US20120302558A1
(en)
*
|
2010-07-13 |
2012-11-29 |
Sangamesh Badiger |
Oxazine derivatives and their use in the treatment of neurological disorders
|
US9446029B2
(en)
|
2010-07-27 |
2016-09-20 |
Colorado State University Research Foundation |
Use of NK-1 receptor antagonists in management of visceral pain
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
ES2376564B1
(es)
|
2010-08-12 |
2013-01-24 |
Manuel Vicente Salinas Martín |
Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
|
DK2606134T3
(da)
|
2010-08-17 |
2019-07-22 |
Sirna Therapeutics Inc |
RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US8524897B2
(en)
|
2011-01-12 |
2013-09-03 |
Novartis Ag |
Crystalline oxazine derivative
|
AP3807A
(en)
|
2011-01-13 |
2016-09-30 |
Novartis Ag |
Novel heterocyclic derivatives and their use in the treatment of neurological disorders
|
CN102127031B
(zh)
*
|
2011-01-17 |
2012-10-17 |
江苏江神药物化学有限公司 |
一种麻黄碱类化合物季胺盐及其合成方法和应用
|
US9067924B2
(en)
*
|
2011-03-04 |
2015-06-30 |
Hoffmann-La Roche Inc. |
1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
|
FR2973031B1
(fr)
*
|
2011-03-23 |
2013-11-29 |
Univ Strasbourg |
Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
|
EP2688901B1
(en)
*
|
2011-03-25 |
2019-05-08 |
Université Laval |
INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2012146692A1
(en)
|
2011-04-29 |
2012-11-01 |
Sandoz Ag |
Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
|
CA2837797A1
(en)
*
|
2011-06-07 |
2012-12-13 |
F. Hoffmann-La Roche Ag |
[1,3]oxazines
|
EP2729147B1
(en)
|
2011-07-04 |
2017-09-06 |
IRBM - Science Park S.p.A. |
Nk-1 receptor antagonists for treating corneal neovascularisation
|
CN102977142B
(zh)
*
|
2011-09-02 |
2017-03-29 |
江苏豪森药业集团有限公司 |
福沙匹坦二甲葡胺的制备方法
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2837381A4
(en)
|
2011-12-13 |
2015-12-09 |
Servicio Andaluz De Salud |
USE OF AGENTS MODIFYING THE PERITUMORAL ENVIRONMENT FOR THE TREATMENT OF CANCER
|
US8338413B1
(en)
|
2012-03-07 |
2012-12-25 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
WO2013168176A2
(en)
*
|
2012-03-30 |
2013-11-14 |
Glenmark Generics Limited |
Process for preparation of fosaprepitant and salt thereof
|
CZ304982B6
(cs)
*
|
2012-04-30 |
2015-03-11 |
Zentiva, K.S. |
Způsob přípravy a čištění nových polymorfů intermediátu fosaprepitantu
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
CN102675369B
(zh)
*
|
2012-05-16 |
2017-07-11 |
北京华众思康医药技术有限公司 |
一种制备[3‑[(2r)‑[(1r)‑1‑[3,5‑二(三氟甲基)苯基]乙氧基]‑3(s)‑(4‑氟苯基)吗啉‑4‑基]甲基]‑5‑氧代‑4,5‑二氢‑[1,2,4]‑***‑1‑基]膦酸一苄酯的新方法
|
US10328022B2
(en)
*
|
2012-05-31 |
2019-06-25 |
Repros Therapeutics Inc. |
Formulations and methods for vaginal delivery of antiprogestins
|
SI2866797T1
(sl)
|
2012-07-06 |
2020-08-31 |
Pharmathen S.A. |
Stabilni injekcijski farmacevtski sestavek antagonista neurokinin 1 receptorja in postopek za njegovo pripravo
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
CA2889977A1
(en)
*
|
2012-10-29 |
2014-05-08 |
Allergan, Inc. |
Phosphate esters of bimatoprost and the prostamides
|
US9126998B2
(en)
|
2012-11-05 |
2015-09-08 |
Bayer Pharma AG |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US8778964B2
(en)
|
2012-11-05 |
2014-07-15 |
Bayer Pharma Aktiengesellschaft |
Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
|
US8796305B2
(en)
|
2012-11-05 |
2014-08-05 |
Bayer Pharma Aktiengesellschaft |
Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US9624214B2
(en)
|
2012-11-05 |
2017-04-18 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
AU2013352568B2
(en)
|
2012-11-28 |
2019-09-19 |
Merck Sharp & Dohme Llc |
Compositions and methods for treating cancer
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
ES2493693B1
(es)
|
2013-02-11 |
2015-07-07 |
Servicio Andaluz De Salud |
Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
|
US20160009755A1
(en)
*
|
2013-03-01 |
2016-01-14 |
Revlon Consumer Products Corporation |
Cyrrhetinic alkyl esters and protected derivatives thereof
|
PT3461834T
(pt)
|
2013-03-13 |
2021-09-10 |
Sage Therapeutics Inc |
Esteroides neuroativos
|
KR20150127720A
(ko)
|
2013-03-14 |
2015-11-17 |
유니버시티 오브 매릴랜드, 발티모어 |
안드로겐 수용체 하향 조절제 및 그의 용도
|
EP2987799B1
(en)
*
|
2013-04-18 |
2020-04-08 |
Xi'an Libang Pharmaceutical Technology Co.,ltd. |
Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
|
EP3004094B1
(de)
|
2013-06-04 |
2017-03-01 |
Bayer Pharma Aktiengesellschaft |
3-aryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
|
BR112016002970A2
(pt)
|
2013-08-12 |
2017-09-12 |
Tokai Pharmaceuticals Inc |
biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CN105899223A
(zh)
|
2013-10-28 |
2016-08-24 |
加利福尼亚大学董事会 |
转移性***癌的治疗
|
CN104650142B
(zh)
*
|
2013-11-25 |
2018-06-22 |
山东新时代药业有限公司 |
一种福沙匹坦二甲葡胺的制备方法
|
CN103694146B
(zh)
*
|
2013-12-04 |
2015-10-28 |
深圳万乐药业有限公司 |
2-(2-氯-1-亚乙基)酰肼甲酸甲酯的制备方法
|
ES2541870B1
(es)
|
2013-12-27 |
2016-05-12 |
Servicio Andaluz De Salud |
Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
|
US20160324881A1
(en)
|
2013-12-30 |
2016-11-10 |
Oncoprevent Gmbh |
Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
|
JP2017507140A
(ja)
|
2014-02-19 |
2017-03-16 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
3−(ピリミジン−2−イル)イミダゾ[1,2−a]ピリジン
|
WO2015140199A1
(de)
|
2014-03-21 |
2015-09-24 |
Bayer Pharma Aktiengesellschaft |
Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
|
TW201613888A
(en)
|
2014-09-26 |
2016-04-16 |
Helsinn Healthcare Sa |
Crystalline forms of an NK-1 antagonist
|
CA2969268A1
(en)
|
2014-12-02 |
2016-06-09 |
Bayer Pharma Aktiengesellschaft |
Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
|
CN108135911B
(zh)
|
2015-07-06 |
2021-06-25 |
萨奇治疗股份有限公司 |
氧甾醇及其使用方法
|
US10610532B2
(en)
|
2015-08-03 |
2020-04-07 |
Leiutis Pharmaceuticals Pvt. Ltd. |
Liquid formulations of fosaprepitant
|
US10005803B2
(en)
|
2015-10-06 |
2018-06-26 |
Helsinn Healthcare Sa |
Crystalline forms of fosnetupitant
|
US9913853B2
(en)
|
2015-11-03 |
2018-03-13 |
Cipla Limited |
Stabilized liquid fosaprepitant formulations
|
EP3383829B1
(en)
|
2015-12-01 |
2020-10-21 |
Piramal Enterprises Limited |
A process for preparation of fosaprepitant dimeglumine and an intermediate thereof
|
CN105837526B
(zh)
*
|
2016-01-22 |
2018-02-27 |
浙江工业大学 |
一种阿瑞吡坦重要合成中间体(2s,3r)‑4‑苄基‑3‑(4‑氟苯基)吗啉‑2‑醇的制备方法
|
ES2921010T3
(es)
|
2016-04-01 |
2022-08-16 |
Sage Therapeutics Inc |
Oxisteroles y procedimientos de uso de los mismos
|
WO2017193046A1
(en)
|
2016-05-06 |
2017-11-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
CN107353303B
(zh)
|
2016-05-09 |
2020-09-01 |
上海奥博生物医药技术有限公司 |
一种福沙匹坦磷酸酯中间体的制备方法
|
BR112018074655B1
(pt)
|
2016-06-06 |
2024-02-15 |
Helsinn Healthcare Sa |
Formulação injetável de fosnetupitanto, método de fabricação de uma formulação e uso de uma formulação injetável
|
PL3481846T3
(pl)
|
2016-07-07 |
2021-12-20 |
Sage Therapeutics, Inc. |
11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
|
US11149056B2
(en)
|
2016-09-30 |
2021-10-19 |
Sage Therapeutics, Inc. |
C7 substituted oxysterols and methods of use thereof
|
JP2019532079A
(ja)
|
2016-10-18 |
2019-11-07 |
セージ セラピューティクス, インコーポレイテッド |
オキシステロールおよびその使用方法
|
US11149054B2
(en)
|
2016-10-18 |
2021-10-19 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
KR20200002899A
(ko)
|
2017-04-10 |
2020-01-08 |
체이스 테라퓨틱스 코포레이션 |
시누클레인병변을 치료하기 위한 nk1-길항제 배합물 및 방법
|
JP7158425B2
(ja)
|
2017-06-30 |
2022-10-21 |
チェイス セラピューティクス コーポレイション |
Nk-1アンタゴニスト組成物およびうつ病の処置における使用法
|
EP3672964A4
(en)
|
2017-08-21 |
2021-05-26 |
Leiutis Pharmaceuticals Pvt. Ltd. |
NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
|
CN109694390A
(zh)
*
|
2017-10-24 |
2019-04-30 |
齐鲁制药有限公司 |
一种福沙匹坦氮氧化物
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
WO2019162519A1
(en)
|
2018-02-26 |
2019-08-29 |
Ospedale San Raffaele S.R.L. |
Nk-1 antagonists for use in the treatment of ocular pain
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
EP4117673A1
(en)
|
2020-03-11 |
2023-01-18 |
Ospedale San Raffaele S.r.l. |
Treatment of stem cell deficiency
|
BR112022018876A2
(pt)
|
2020-04-03 |
2022-11-22 |
Nerre Therapeutics Ltd |
Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
|
WO2021245512A1
(en)
|
2020-06-02 |
2021-12-09 |
Nerre Therapeutics Limited |
Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
|
KR20230110283A
(ko)
|
2020-11-19 |
2023-07-21 |
니폰 카야쿠 가부시키가이샤 |
혈관 장애를 유발하는 수용성 의약 함유 조성물, 혈관 장애를 유발하는 수용성 의약 함유 투여액 조제용 용액, 키트, 혈관 장애 억제제 및 비이온계 계면활성제 함유 용액
|
EP4052696A1
(en)
|
2021-03-04 |
2022-09-07 |
Extrovis AG |
Stable ready-to-use parenteral compositions of fosaprepitant
|
CN113582982B
(zh)
*
|
2021-06-15 |
2023-06-16 |
山东罗欣药业集团股份有限公司 |
一种nk1受体拮抗剂的制备方法
|